文献速递临床试验与 GCP基础与转化研究

褪黑素治疗中度COVID-19患者有效性与安全性的随机对照试验方案结构化摘要

Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-10-26

该方案计划在伊朗一家医院开展单中心、随机、双盲、安慰剂对照平行组试验,纳入60例确诊中度COVID-19住院患者,比较标准治疗联合褪黑素50 mg每日一次共7天与标准治疗联合安慰剂的疗效与安全性,主要结局为7天内临床症状恢复率、氧饱和度及血清炎症指标改善。

要点

  • 研究对象为确诊SARS-CoV-2感染、中度肺炎且住院≤48小时、年龄≥20岁的患者。
  • 干预组在伊朗卫生部标准方案基础上加用褪黑素50 mg每日一次,疗程7天。
  • 主要结局为7天内临床症状恢复率、氧饱和度及CRP、TNF-α、IL-1β、IL-6改善。

核心结论

  • 该方案旨在评估褪黑素联合标准治疗对中度COVID-19患者临床症状和血清炎症参数的疗效与安全性。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照、平行组临床试验,在伊朗Bandar Abbas的Shahid Mohammadi医院开展。
  • 计划随机纳入60例患者,两组各30例,采用区组随机化按1:1比例分配,每组区组10例。
  • 研究纳入标准包括年龄≥20岁、SARS-CoV-2 PCR阳性、中度COVID-19肺炎需住院、住院≤48小时并签署知情同意。
  • 排除标准包括慢性高血压、糖尿病、癫痫、抑郁、慢性肝炎、肝硬化、胆汁淤积性肝病等基础疾病及重型和危重型COVID-19肺炎。
  • 排除近30天内使用华法林、皮质类固醇、激素类药物、酒精、其他抗病毒及研究性药物和非法药物者,以及已知褪黑素过敏、妊娠和哺乳者。

关键数值与推荐

  • 干预组:伊朗卫生部COVID-19标准治疗方案联合褪黑素胶囊50 mg每日一次,共7天。
  • 对照组:伊朗卫生部COVID-19标准治疗方案联合褪黑素类似安慰剂胶囊每日一粒,共7天。
  • 主要结局:随机分组后7天内临床症状恢复率、氧饱和度及血清炎症参数(CRP、TNF-α、IL-1β、IL-6)改善。
  • 次要结局:随机分组后7天内临床和辅助检查特征改善时间及严重药物不良反应发生率。

临床怎么用

  • 该方案为褪黑素用于中度COVID-19的随机对照试验设计,尚不能提供疗效或安全性结论,临床实践应等待试验结果。

局限性

  • 该文件为试验方案结构化摘要,未报告试验结果或疗效安全性数据。
  • 单中心设计,计划样本量60例,可能限制结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We will evaluate the efficacy and safety of Melatonin, compared to the standard therapeutic regimen on clinical symptoms and serum inflammatory parameters in patients with confirmed COVID-19, who are moderately ill. TRIAL DESIGN: This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a parallel-group design conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran. PARTICIPANTS: All patients admitted to Severe Acute Respiratory Syndrome Departments of Shahid Mohammadi Hospital, Bandar Abbas, Iran will be screened for the following criteria. INCLUSION CRITERIA: 1. Age ≥20 years 2. Confirmed SARS-CoV-2 diagnosis (positive polymerase chain reaction). 3. Moderate COVID-19 pneumonia (via computed tomography and or X-ray imaging), requiring hospitalization. 4. Hospitalized ≤48 hours. 5. Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm. EXCLUSION CRITERIA: 1. Underlying diseases, including chronic hypertension, diabetes mellitus, seizure, depression, chronic hepatitis, cirrhosis, and cholestatic liver diseases. 2. Severe and critical COVID-19 pneumonia. 3. Use of warfarin, corticosteroids, hormonal drugs, alcohol, other antiviral and investigational medicines, and illegal drugs (during the last 30 days). 4. History of known allergy to Melatonin. 5. Pregnancy and breastfeeding. INTERVENTION AND COMPARATOR: Intervention group: The standard treatment regimen for COVID-19, according to the Iranian Ministry of Health and Medical Education's protocol, along with Melatonin capsules at a dose of 50 mg daily for a period of seven days. CONTROL GROUP: The standard therapeutic regimen for COVID-19 along with Melatonin-like placebo capsules at a dose of one capsule daily for a period of seven days. Both Melatonin and placebo capsules were prepared at the Faculty of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. MAIN OUTCOMES: The primary outcomes are the recovery rate of clinical symptoms and oxygen saturation as well as improvement of serum inflammatory parameters, including C-reactive protein, tumor necrosis factor-alpha (TNF-ɑ), interleukin-1β (IL-1β), and IL-6 within seven days of randomization. The secondary outcomes are the time to improve clinical and paraclinical features along with the incidence of serious adverse drug reactions within seven days of randomization. RANDOMIZATION: Included patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 10 patients). This randomization method ensures a balanced allocation between the arms during the study. A web-based system will generate random numbers for the allocation sequence and concealment of participants. Each number relates to one of the study arms. BLINDING (MASKING): All study participants, clinicians, nurses, research coordinators, and those analyzing the data are blinded to the group assignment. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 60 patients randomized into two groups (30 in each group). TRIAL STATUS: The trial protocol is Version 1.0, August 14, 2020. Recruitment began August 22, 2020, and is anticipated to be completed by November 30, 2020. TRIAL REGISTRATION: The trial protocol has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20200506047323N5 ". The registration date was 14 August 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ziaei A, Davoodian P, Dadvand H, et al. Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33106171. doi:10.1186/s13063-020-04737-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。